News: Abiomed Inc (ABMD.OQ)
ABMD.OQ on NASDAQ Stock Exchange Global Select Market
24.15USD
1 Aug 2013
24.15USD
1 Aug 2013
Price Change (% chg)
$-0.93 (-3.71%)
$-0.93 (-3.71%)
Prev Close
$25.08
$25.08
Open
$25.22
$25.22
Day's High
$25.22
$25.22
Day's Low
$22.94
$22.94
Volume
422,319
422,319
Avg. Vol
118,161
118,161
52-wk High
$25.24
$25.24
52-wk Low
$11.82
$11.82
Select another date:
Wed, Apr 17 2013
BRIEF-Abiomed shares up 7.2 pct, volume high
NEW YORK, April 17 - Abiomed Inc : * Shares up 7.2 percent, volume above 25-day average
Select another date:
Press Releases
- Glancy Binkow & Goldberg LLP Announces Lead Plaintiff Deadline in the Class Action Lawsuit AgainstAbiomed, Inc.
- United Natural Foods Set to Join the S&P MidCap 400; Abiomed & Ixia to Join S&P SmallCap 600
- Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In ABIOMED, Inc. To Contact The Firm
- Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Abiomed, Inc.
- Investor Alert: Following Food and Drug Administration Panel Vote, Hagens Berman Reminds Abiomed, Inc. Investors of Jan. 15, 2013, Lead Plaintiff Deadline in Class-Action Lawsuit
- FDA 515i Reclassification Panel Recommends Class III Status for Temporary Ventricular Support Devices in the Non-Roller Type Cardiopulmonary Bypass Blood Pumps Category
- Milberg LLP Announces Pendency of Class Action Lawsuits Filed Against Abiomed, Inc. (ABMD) -- AbiomedLawsuit.com
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against Blyth, Inc. (BTH), Align Technology, Inc. (ALGN) and Abiomed, Inc. (ABMD) and Investigation of Peregrine Pharmaceuticals, Inc. (PPHM)
- Newman Ferrara LLP Announces That A Securities Fraud Class Action Lawsuit Has Been Filed Against ABIOMED, Inc.
- Hagens Berman Investigates Impact of FDA Abiomed Impella Statements, Reminds Investors of Jan. 15, 2013, Lead Plaintiff Deadline in Securities Class Action

